Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Primary care medicine-Part II : Practice-oriented diagnosis and treatment pathways].

Der Internist·2021

Same author

[Janus kinase inhibitors : State of the art in clinical use and future perspectives].

Zeitschrift fur Rheumatologie·2020

Same author

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

BMC rheumatology·2020

Same author

[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].

Der Internist·2020

Same author

[Polyneuropathies-many causes, complicated treatment].

Der Internist·2020

Same author

[Primary care medicine-Part I : Practice-oriented diagnosis and treatment pathways].

Der Internist·2020

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

[Selective co-stimulation blockade. CTLA4-Ig (Abatacept)].

R Alten¹, E Märker-Hermann

¹Klinik Innere Medizin II, Rheumatologie, klinische Immunologie und Osteologie, Schlosspark-Klinik, Akademisches Lehrkrankenhaus, Charité-Universitätsmedizin Berlin, 14059 Berlin, Deutschland. rieke.alten@schlosspark-klinik.de

Zeitschrift Fur Rheumatologie

|August 13, 2010

Summary

Abatacept effectively treats rheumatoid arthritis (RA) in patients resistant to other therapies. This targeted therapy shows comparable efficacy in patients refractory to TNF-alpha blockade and disease-modifying antirheumatic drugs (DMARDs), with a favorable safety profile.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8⁺ T Cell Responses

Published on: May 6, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8⁺ T Cell Responses

Published on: May 6, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

Immunology
Rheumatology
Pharmacology

Context:

Rheumatoid arthritis (RA) poses challenges, particularly for patients unresponsive to existing treatments like TNF-alpha blockade.
Abatacept offers a targeted therapy option for RA management.
The European Union recently approved abatacept for disease-modifying antirheumatic drug-resistant (DMARD-IR) patients.

Purpose:

To evaluate the efficacy and safety of abatacept in rheumatoid arthritis (RA) patients.
To assess abatacept's utility in patients refractory to TNF-alpha blockade (TNF-IR) and DMARD-IR patients.
To compare treatment pathways targeted by abatacept and TNF-alpha blockade.

Summary:

Abatacept, a CTLA4-Ig fusion protein, blocks T-cell activation crucial for RA pathogenesis.
Studies demonstrate abatacept's efficacy in both TNF-IR and DMARD-IR RA populations.
Response rates in TNF-IR patients were similar to those in DMARD-IR patients, suggesting distinct therapeutic pathways.

Impact:

Abatacept expands treatment options for difficult-to-treat RA patients.
The drug's safety profile, with malignancy and opportunistic infection rates comparable to RA populations, supports its clinical use.
Distinct therapeutic pathways implied by similar efficacy suggest potential for combination therapies or sequential treatment strategies.